Project Grant R01AG099051
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $420K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Institute on Aging awarded University of Massachusetts Medical School $445,130 on January 1, 2026, under the Aging Research program (CFDA 93.866) to support research elucidating the mechanisms by which MS4A genes regulate neurodegeneration in Alzheimer's disease and related disorders. The research investigates how genetic deletion and polymorphisms of MS4A family genes—particularly MS4A6C, MS4A4A, MS4A4E, and MS4A6E—affect disease progression across multiple neurodegenerative...
- The National Institute on Aging awarded Rensselaer Polytechnic Institute $698,712 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate apolipoprotein E and reelin interactions in Alzheimer's disease pathology. The research tests the hypothesis that APOE E4 competes with reelin for receptor and heparan sulfate binding, thereby reducing protective reelin signaling and increasing Alzheimer's disease risk. Work includes mechanistic studies using split luciferase assays...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $357,000 under the Aging Research program (CFDA 93.866) on September 1, 2026, to investigate endothelial pannexin1-induced inflammation in Alzheimer's disease. The research tests the hypothesis that amyloid-beta upregulates cerebral endothelial pannexin1 expression, which promotes vascular dysfunction and Alzheimer's disease progression through increased neuroinflammation and...
- The National Institute on Aging awarded Weill Medical College of Cornell University a $3.252734 million Cooperative Agreement (UG3AG098024) on April 1, 2026, to conduct a Phase 1A clinical trial of gene therapy for APOE4 homozygous Alzheimer's disease. The recipient will execute a safety and dose-ranging trial administering AAVRH.10HAPOE2CH—an adeno-associated virus vector carrying a modified protective APOE variant—via cerebrospinal fluid injection to APOE4 homozygotes with early-onset...
- The National Institute on Aging, under the Department of Health and Human Services, awarded $446,875 to the University of Pennsylvania on March 15, 2026, under the Aging Research program (CFDA 93.866) to identify short RNAs that prevent and reverse aberrant phase transitions of TAF15, an RNA-binding protein implicated in approximately 10 percent of frontotemporal dementia cases. The project, R21AG091143, funds research to develop short RNAs of 25 to 34 nucleotides that antagonize pathological...
- The National Institute on Aging awarded The Johns Hopkins University $427,625 under the Aging Research program (CFDA 93.866) on September 1, 2026, for research targeting glial cholesteryl ester accumulation as a treatment strategy for apolipoprotein E4–associated Alzheimer's disease. The research focuses on ACAT1/SOAT1, the enzyme that converts free cholesterol into cholesteryl esters for storage in lipid droplets within glial cells. The project proposes conjugating eflucimibe, a potent...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $1,613,176 on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate the impact of M6A RNA modifications in Alzheimer's disease and tauopathies. The research will characterize N6-methyladenosine (M6A) RNA modifications and their downstream functional consequences in post-mortem brain tissue from subjects with Alzheimer's disease and other tauopathies, leveraging...
- The National Institute on Aging awarded $128,250 to Weill Medical College of Cornell University on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate modifiers of human microglia-neuron interplay in tau propagation in vivo. The research employs a human neuron-microglia chimera platform that integrates human neurons, astrocytes, and microglia into the mouse brain to model Alzheimer's disease and frontotemporal dementia pathology. Aim 1 investigates molecular...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $681,908 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate protective mechanisms of UFM1-dependent IRE1 signaling in tauopathies, with work performance in San Francisco, California through November 30, 2030. The project addresses tau protein aggregation in Alzheimer's disease and related tauopathies by elucidating molecular mechanisms linking the ufmylation pathway...